X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (27) 27
male (23) 23
middle aged (23) 23
female (22) 22
adult (21) 21
index medicus (21) 21
adolescent (15) 15
aged (15) 15
risk factors (14) 14
disease-free survival (11) 11
hematology (11) 11
oncology (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
cancer (10) 10
treatment outcome (10) 10
young adult (10) 10
aged, 80 and over (9) 9
chemotherapy (9) 9
antineoplastic combined chemotherapy protocols - administration & dosage (8) 8
disease (8) 8
lymphomas (8) 8
non-hodgkins-lymphoma (8) 8
rituximab (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
cyclophosphamide - administration & dosage (7) 7
doxorubicin - administration & dosage (7) 7
lymphoma, large b-cell, diffuse - drug therapy (7) 7
prednisone - administration & dosage (7) 7
survival (7) 7
[ sdv.can ] life sciences [q-bio]/cancer (6) 6
radiotherapy (6) 6
vincristine - administration & dosage (6) 6
cyclophosphamide (5) 5
cyclophosphamide - adverse effects (5) 5
doxorubicin - adverse effects (5) 5
drug administration schedule (5) 5
elderly-patients (5) 5
hematology, oncology and palliative medicine (5) 5
life sciences (5) 5
lymphoma (5) 5
lymphoma, large b-cell, diffuse - mortality (5) 5
prednisone - adverse effects (5) 5
prognosis (5) 5
prospective studies (5) 5
risk assessment (5) 5
survival analysis (5) 5
transplantation (5) 5
vincristine (5) 5
antibodies, monoclonal, murine-derived - therapeutic use (4) 4
antineoplastic agents - therapeutic use (4) 4
bleomycin - administration & dosage (4) 4
care and treatment (4) 4
clinical stage-i (4) 4
clinical trials (4) 4
combination chemotherapy (4) 4
combined-modality (4) 4
cooperative group (4) 4
doxorubicin (4) 4
kaplan-meier estimate (4) 4
prednisone (4) 4
randomized-trials (4) 4
response criteria (4) 4
survival rate (4) 4
therapy (4) 4
vinblastine (4) 4
vincristine - adverse effects (4) 4
[sdv.can]life sciences [q-bio]/cancer (3) 3
aged patients (3) 3
anthracyclines (3) 3
antibodies, monoclonal, murine-derived - administration & dosage (3) 3
b-cell lymphoma (3) 3
bleomycin (3) 3
bleomycin - adverse effects (3) 3
cardiac & cardiovascular systems (3) 3
combined modality therapy (3) 3
cyclophosphamide - therapeutic use (3) 3
dacarbazine - administration & dosage (3) 3
doxorubicin - therapeutic use (3) 3
early stage (3) 3
etoposide - administration & dosage (3) 3
follow-up studies (3) 3
hemic and lymphatic diseases (3) 3
hodgkin disease - drug therapy (3) 3
hodgkin disease - therapy (3) 3
hodgkin lymphoma (3) 3
lymphoma, large b-cell, diffuse - diagnosis (3) 3
multivariate analysis (3) 3
patient outcomes (3) 3
patients (3) 3
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (3) 3
prednisone - therapeutic use (3) 3
procarbazine - administration & dosage (3) 3
randomized controlled trial (3) 3
regimen (3) 3
research (3) 3
surveys and questionnaires (3) 3
time factors (3) 3
treatment efficacy (3) 3
vinblastine - administration & dosage (3) 3
abridged index medicus (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Summary Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESPONSE CRITERIA | AGGRESSIVE LYMPHOMAS | POOR-PROGNOSIS | NON-HODGKINS-LYMPHOMA | REGIMEN | YOUNG-PATIENTS | ELDERLY-PATIENTS | DES-LYMPHOMES | TRANSPLANTATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 460 - 468
Summary Background Diffuse large B-cell lymphoma is a common cancer in elderly patients. Although treatment has been standardised in younger patients, no... 
Hematology, Oncology and Palliative Medicine | MAINTENANCE RITUXIMAB | COLONY-STIMULATING FACTOR | PROGNOSTIC-FACTORS | RESPONSE CRITERIA | ONCOLOGY | AGGRESSIVE LYMPHOMAS | MALIGNANT-LYMPHOMAS | NON-HODGKINS-LYMPHOMA | COMPREHENSIVE GERIATRIC ASSESSMENT | DETUDE-DES-LYMPHOMES | CHOP CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Aged, 80 and over | Vincristine - administration & dosage | Female | France | Odds Ratio | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Assessment | Risk Factors | Rituximab | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Analysis of Variance | Belgium | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - adverse effects | Doxorubicin - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Oncology, Experimental | Aged patients | Product development | Prednisone | Lymphomas | Research | Cancer | Toxicity | Albumin | Clinical trials | Multivariate analysis | Doxorubicin | Survival | Vincristine | Side effects | Motivation | Age | rituximab | B-cell lymphoma | Geriatrics | Neutropenia
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 525 - 533
Journal Article
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2012, Volume 30, Issue 3, pp. 291 - 299
Journal Article
American Journal of Hematology, ISSN 0361-8609, 02/2016, Volume 91, Issue 2, pp. 179 - 184
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4132 - 4132
Abstract Introduction: Clinical evolution of classical Hodgkin lymphoma (cHL) cannot be always predicted by clinical, biological or radiological parameters.... 
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2017, Volume 4, Issue 1, pp. e46 - e55
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2016, Volume 34, Issue 6, pp. 572 - 580
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 31, pp. 3854 - 3863
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 3663 - 3663
Abstract Introduction There are some evidences that blood transfusions, either red blood cell (RBC) or platelet, could impact survival of patients affected... 
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 2202 - 2202
Abstract Introduction Anemia is a common feature at diagnosis of patients with lymphoid malignancies and has been previously described as an important... 
Journal Article